Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician
Journal of Clinical Medicine · 24.04.2023 · 12 (9) · 3096
DOI: 10.3390/jcm12093096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.04.2023. Verfasst von Margherita Barbuti und 7 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Psychiatric Unit, Department of Clinical and Experimental Medicine, Santa Chiara University Hospital, University of Pisa, 56100 Pisa, Italy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Adults with attention deficit/hyperactivity disorder (ADHD) often present psychiatric comorbidities and, in particular, substance use disorder (SUD). ADHD-SUD comorbidity is characterized by greater severity of both disorders, earlier age of onset, higher likelihood of polydrug-abuse and suicidal behaviors, more hospitalizations, and lower treatment adherence. At the present stage, research focused on the pharmacological management of ADHD with comorbid SUD in both adolescents and adults is still lacking. Furthermore, while the short-term effects of stimulants are well studied, less is known about the chronic effects of these drugs on dopamine signaling. Current available evidence is consistent in reporting that high doses of stimulant medications in ADHD-SUD subjects have a mild to moderate efficacy on ADHD symptoms. Some data suggest that pharmacological treatment with stimulants may be beneficial for both ADHD symptoms and comorbid cocaine or amphetamine use. However, in the long run, stimulant medications may have a potential risk for misuse. For the absence of potential misuse, atomoxetine is often recommended for ADHD with comorbid cocaine or amphetamine use disorder. However, its efficacy in reducing addictive behavior is not demonstrated. In subjects with other subtypes of SUD, both atomoxetine and stimulant drugs seem to have scarce impact on addictive behavior, despite the improvement in ADHD symptomatology. In this population, ADHD treatment should be combined with SUD-specific strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 2nd Psychiatric Unit, Department of Clinical and Experimental Medicine, Santa Chiara University Hospital, University of Pisa, 56100 Pisa, Italy.
- Section of Psychiatry, Department of Psychiatry and Addictions, North-Western Tuscany Local Health Unit, Tuscany NHS, Versilia Zone, Via Aurelia 335, 55041 Lido di Camaiore, Italy.
ORCID-Profile: Margherita Barbuti, Marco Maiello, Alessandro Pallucchini, Giulio E Brancati, Angelo G I Maremmani, Giulio Perugi, Icro Maremmani
Zitieren
APA
Barbuti, M., Maiello, M., Spera, V., Pallucchini, A., Brancati, G. E., Maremmani, A. G. I., Perugi, G., & Maremmani, I. (2023). Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician. Journal of Clinical Medicine, 12(9), 3096. https://doi.org/10.3390/jcm12093096
Vancouver
Barbuti M, Maiello M, Spera V, Pallucchini A, Brancati GE, Maremmani AGI, et al. Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician. Journal of Clinical Medicine. 2023;12(9):3096. doi:10.3390/jcm12093096
BibTeX
@article{Barbuti2023,
author = {Barbuti, Margherita and Maiello, Marco and Spera, Vincenza and Pallucchini, Alessandro and Brancati, Giulio E and Maremmani, Angelo G I and Perugi, Giulio and Maremmani, Icro},
title = {Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {9},
pages = {3096},
doi = {10.3390/jcm12093096}
}
EUVIMED